Bristol-Myers Squibb CEO Chris Boerner detailed the pharmaceutical giant’s bundle of recent acquisitions in a Monday interview with CNBC’s Jim Cramer, and
Tag: Mirati Therapeutics Inc
Cramer names biopharma companies as industry mergers start to accrue
CNBC’s Jim Cramer on Friday pointed out the number of biopharma mergers and acquisitions that have closed or been announced over the
Stocks making biggest moves midday: United Airlines, Spotify
The USS Truxtun (DDG-103) destroyer sits in dry dock at the General Dynamics Corp. NASSCO shipyard facility on the Elizabeth River in
Bristol-Myers Squibb to acquire Mirati in a $4.8 billion deal
Bristol-Myers Squibb is set to acquire cancer drugmaker Mirati Therapeutics for $58 per share in cash, representing a $4.8 billion equity value.
No More Posts Available.
No more pages to load.